Caisse DE Depot ET Placement DU Quebec Purchases New Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 69,864 shares of the company’s stock, valued at approximately $23,321,000.

Several other hedge funds also recently modified their holdings of MEDP. Tidal Investments LLC raised its position in shares of Medpace by 16.2% during the 1st quarter. Tidal Investments LLC now owns 874 shares of the company’s stock valued at $353,000 after acquiring an additional 122 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of Medpace by 235.0% during the first quarter. Cetera Investment Advisers now owns 11,494 shares of the company’s stock worth $4,645,000 after buying an additional 8,063 shares during the period. Cetera Advisors LLC grew its holdings in shares of Medpace by 162.4% during the first quarter. Cetera Advisors LLC now owns 2,608 shares of the company’s stock worth $1,054,000 after buying an additional 1,614 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Medpace by 58.4% in the second quarter. GAMMA Investing LLC now owns 236 shares of the company’s stock valued at $97,000 after purchasing an additional 87 shares during the last quarter. Finally, CWM LLC lifted its position in Medpace by 38.8% during the 2nd quarter. CWM LLC now owns 2,323 shares of the company’s stock worth $957,000 after buying an additional 649 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.5 %

Shares of MEDP stock opened at $340.63 on Monday. Medpace Holdings, Inc. has a 12 month low of $268.80 and a 12 month high of $459.77. The firm has a market capitalization of $10.59 billion, a price-to-earnings ratio of 29.83, a PEG ratio of 1.88 and a beta of 1.37. The business’s 50-day moving average price is $337.82 and its 200-day moving average price is $370.98.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same period last year, the company earned $2.22 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent analyst reports. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and cut their price objective for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. TD Cowen lowered their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Robert W. Baird boosted their target price on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $380.56.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.